BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccalà G, Lotteau V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002;76:6919-28. [PMID: 12072493 DOI: 10.1128/jvi.76.14.6919-6928.2002] [Cited by in Crossref: 477] [Cited by in F6Publishing: 248] [Article Influence: 25.1] [Reference Citation Analysis]
Number Citing Articles
1 Del Campo JA, Romero-Gómez M. Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. World J Gastroenterol 2015; 21(38): 10776-10782 [PMID: 26478669 DOI: 10.3748/wjg.v21.i38.10776] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
2 Razzaq Z, Malik A. Viral load is associated with abnormal serum levels of micronutrients and glutathione and glutathione-dependent enzymes in genotype 3 HCV patients. BBA Clin 2014;2:72-8. [PMID: 26674880 DOI: 10.1016/j.bbacli.2014.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Poenisch M, Metz P, Blankenburg H, Ruggieri A, Lee JY, Rupp D, Rebhan I, Diederich K, Kaderali L, Domingues FS, Albrecht M, Lohmann V, Erfle H, Bartenschlager R. Identification of HNRNPK as regulator of hepatitis C virus particle production. PLoS Pathog 2015;11:e1004573. [PMID: 25569684 DOI: 10.1371/journal.ppat.1004573] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
4 Guo J, Yan R, Xu G, Li W, Zheng C. Construction of the Vero cell culture system that can produce infectious HCV particles. Mol Biol Rep 2009;36:111-20. [PMID: 17960493 DOI: 10.1007/s11033-007-9158-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
5 Farquhar MJ, McKeating JA. Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat. 2008;15:849-854. [PMID: 19087224 DOI: 10.1111/j.1365-2893.2008.01051.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
6 Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA. 2002;99:15669-15674. [PMID: 12441396 DOI: 10.1073/pnas.202608199] [Cited by in Crossref: 502] [Cited by in F6Publishing: 478] [Article Influence: 26.4] [Reference Citation Analysis]
7 Lu G, Yao M, Zhou Y, Tao X. Purification of Rice Stripe Virus. Bio Protoc 2020;10:e3565. [PMID: 33659536 DOI: 10.21769/BioProtoc.3565] [Reference Citation Analysis]
8 Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368:1907-1917. [PMID: 23675659 DOI: 10.1056/nejmra1213651] [Cited by in Crossref: 325] [Cited by in F6Publishing: 161] [Article Influence: 40.6] [Reference Citation Analysis]
9 Urbaczek AC, Ximenes VF, Afonso A, Generoso WC, Nogueira CT, Tansini A, Cappelini LT, Malagó Júnior W, da Silva FH, da Fonseca LM, da Costa PI. Recombinant hepatitis C virus-envelope protein 2 interactions with low-density lipoprotein/CD81 receptors. Mem Inst Oswaldo Cruz 2015;110:534-42. [PMID: 26018451 DOI: 10.1590/0074-02760140441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Bender D, Hildt E. Effect of Hepatitis Viruses on the Nrf2/Keap1-Signaling Pathway and Its Impact on Viral Replication and Pathogenesis. Int J Mol Sci 2019;20:E4659. [PMID: 31546975 DOI: 10.3390/ijms20184659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
11 Lindenbach BD. Virion assembly and release. Curr Top Microbiol Immunol. 2013;369:199-218. [PMID: 23463202 DOI: 10.1007/978-3-642-27340-7_8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 64] [Article Influence: 3.1] [Reference Citation Analysis]
12 Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol 2015;89:4387-404. [PMID: 25653444 DOI: 10.1128/JVI.02705-14] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
13 Deforges S, Evlashev A, Perret M, Sodoyer M, Pouzol S, Scoazec JY, Bonnaud B, Diaz O, Paranhos-Baccalà G, Lotteau V. Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J Gen Virol. 2004;85:2515-2523. [PMID: 15302945 DOI: 10.1099/vir.0.80071-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
14 Zayas M, Long G, Madan V, Bartenschlager R. Coordination of Hepatitis C Virus Assembly by Distinct Regulatory Regions in Nonstructural Protein 5A. PLoS Pathog 2016;12:e1005376. [PMID: 26727512 DOI: 10.1371/journal.ppat.1005376] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
15 Ryder S. Do high lipids help clearance of hepatitis C? Gut 2007;56:1044-5. [PMID: 17625141 DOI: 10.1136/gut.2006.108845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
16 Benedicto I, Molina-Jiménez F, Moreno-Otero R, López-Cabrera M, Majano PL. Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. World J Gastroenterol 2011; 17(22): 2683-2690 [PMID: 21734774 DOI: 10.3748/wjg.v17.i22.2683] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
17 Pirro M, Bianconi V, Francisci D, Schiaroli E, Bagaglia F, Sahebkar A, Baldelli F. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. J Cell Mol Med 2017;21:3150-61. [PMID: 28722331 DOI: 10.1111/jcmm.13273] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
18 Maillard P, Walic M, Meuleman P, Roohvand F, Huby T, Le Goff W, Leroux-Roels G, Pécheur EI, Budkowska A. Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS One. 2011;6:e26637. [PMID: 22039521 DOI: 10.1371/journal.pone.0026637] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
19 Yang Z, Wang X, Chi X, Zhao F, Guo J, Ma P, Zhong J, Niu J, Pan X, Long G. Neglected but Important Role of Apolipoprotein E Exchange in Hepatitis C Virus Infection. J Virol 2016;90:9632-43. [PMID: 27535051 DOI: 10.1128/JVI.01353-16] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
20 Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol. 2010;84:6615-6625. [PMID: 20427538 DOI: 10.1128/jvi.00417-10] [Cited by in Crossref: 236] [Cited by in F6Publishing: 140] [Article Influence: 21.5] [Reference Citation Analysis]
21 Tarr AW, Urbanowicz RA, Ball JK. The role of humoral innate immunity in hepatitis C virus infection. Viruses. 2012;4:1-27. [PMID: 22355450 DOI: 10.3390/v4010001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
22 Ploen D, Hildt E. Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. World J Gastroenterol 2015; 21(28): 8492-8507 [PMID: 26229393 DOI: 10.3748/wjg.v21.i28.8492] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
23 Law JLM, Logan M, Wong J, Kundu J, Hockman D, Landi A, Chen C, Crawford K, Wininger M, Johnson J, Mesa Prince C, Dudek E, Mehta N, Tyrrell DL, Houghton M. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. J Virol 2018;92:e02141-17. [PMID: 29540595 DOI: 10.1128/JVI.02141-17] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
24 Vercauteren K, Mesalam AA, Leroux-Roels G, Meuleman P. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol 2014; 20(43): 15975-15991 [PMID: 25473151 DOI: 10.3748/wjg.v20.i43.15975] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
25 Paul D, Madan V, Bartenschlager R. Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe. 2014;16:569-579. [PMID: 25525790 DOI: 10.1016/j.chom.2014.10.008] [Cited by in Crossref: 179] [Cited by in F6Publishing: 162] [Article Influence: 25.6] [Reference Citation Analysis]
26 Steinmann D, Barth H, Gissler B, Schürmann P, Adah MI, Gerlach JT, Pape GR, Depla E, Jacobs D, Maertens G. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol. 2004;78:9030-9040. [PMID: 15308699 DOI: 10.1128/JVI.78.17.9030-9040.2004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
27 Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22:826-32. [PMID: 27592089 DOI: 10.1016/j.cmi.2016.08.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
28 Merz A, Long G, Hiet MS, Brügger B, Chlanda P, Andre P, Wieland F, Krijnse-Locker J, Bartenschlager R. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem. 2011;286:3018-3032. [PMID: 21056986 DOI: 10.1074/jbc.m110.175018] [Cited by in Crossref: 259] [Cited by in F6Publishing: 169] [Article Influence: 23.5] [Reference Citation Analysis]
29 Koutsoudakis G, Dragun J, Pérez-Del-Pulgar S, Coto-Llerena M, Mensa L, Crespo G, González P, Navasa M, Forns X. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. PLoS One. 2012;7:e52651. [PMID: 23300734 DOI: 10.1371/journal.pone.0052651] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
30 Coller KE, Berger KL, Heaton NS, Cooper JD, Yoon R, Randall G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 2009;5:e1000702. [PMID: 20041214 DOI: 10.1371/journal.ppat.1000702] [Cited by in Crossref: 131] [Cited by in F6Publishing: 129] [Article Influence: 10.9] [Reference Citation Analysis]
31 Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013;19:17-25. [PMID: 23593605 DOI: 10.3350/cmh.2013.19.1.17] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 10.5] [Reference Citation Analysis]
32 Venkataraman S, Hefferon K, Makhzoum A, Abouhaidar M. Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer? Vaccines (Basel) 2021;9:761. [PMID: 34358177 DOI: 10.3390/vaccines9070761] [Reference Citation Analysis]
33 Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Curr Infect Dis Rep 2017;19:22. [PMID: 28421422 DOI: 10.1007/s11908-017-0578-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
34 Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853 [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
35 Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol. 2011;85:2224-2234. [PMID: 21123377 DOI: 10.1128/jvi.01594-10] [Cited by in Crossref: 111] [Cited by in F6Publishing: 81] [Article Influence: 10.1] [Reference Citation Analysis]
36 Jones DM, McLauchlan J. Hepatitis C virus: assembly and release of virus particles. J Biol Chem. 2010;285:22733-22739. [PMID: 20457608 DOI: 10.1074/jbc.r110.133017] [Cited by in Crossref: 78] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
37 Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 2005;79:11095-104. [PMID: 16103160 DOI: 10.1128/JVI.79.17.11095-11104.2005] [Cited by in Crossref: 212] [Cited by in F6Publishing: 146] [Article Influence: 13.3] [Reference Citation Analysis]
38 Wu C, Gilroy R, Taylor R, Olyaee M, Abdulkarim B, Forster J, O’Neil M, Damjanov I, Wan YJ. Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology. 2011;54:1966-1974. [PMID: 21898497 DOI: 10.1002/hep.24645] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
39 Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, Chaturvedi N, Mohamed MK, Fontanet A. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut. 2007;56:1105-1110. [PMID: 16956918 DOI: 10.1136/gut.2006.091983] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 4.1] [Reference Citation Analysis]
40 Del Campo JA, Rojas &, Romero-Gómez M. Entry of hepatitis C virus into the cell: A therapeutic target. World J Gastroenterol 2012; 18(33): 4481-4485 [PMID: 22969220 DOI: 10.3748/wjg.v18.i33.4481] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
41 Cosset FL, Mialon C, Boson B, Granier C, Denolly S. HCV Interplay with Lipoproteins: Inside or Outside the Cells? Viruses 2020;12:E434. [PMID: 32290553 DOI: 10.3390/v12040434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
42 Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM. Studying hepatitis C virus: making the best of a bad virus. J Virol. 2007;81:8853-8867. [PMID: 17522203 DOI: 10.1128/jvi.00753-07] [Cited by in Crossref: 98] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
43 Moreau I, O'Sullivan H, Murray C, Levis J, Crosbie O, Kenny-Walsh E, Fanning LJ. Separation of Hepatitis C genotype 4a into IgG-depleted and IgG-enriched fractions reveals a unique quasispecies profile. Virol J 2008;5:103. [PMID: 18811965 DOI: 10.1186/1743-422X-5-103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
44 Targett-Adams P, Boulant S, Douglas MW, McLauchlan J. Lipid metabolism and HCV infection. Viruses 2010;2:1195-217. [PMID: 21994676 DOI: 10.3390/v2051195] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
45 Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006; 12(42): 6756-6765 [PMID: 17106922 DOI: 10.3748/wjg.v12.i42.6756] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 91] [Article Influence: 7.0] [Reference Citation Analysis]
46 Wong-Staal F, Syder AJ, McKelvy JF. Targeting HCV entry for development of therapeutics. Viruses 2010;2:1718-33. [PMID: 21994703 DOI: 10.3390/v2081718] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
47 Khattab MA. Targeting host factors: A novel rationale for the management of hepatitis C virus. World J Gastroenterol 2009; 15(28): 3472-3479 [PMID: 19630100 DOI: 10.3748/wjg.15.3472] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
48 Calattini S, Fusil F, Mancip J, Dao Thi VL, Granier C, Gadot N, Scoazec JY, Zeisel MB, Baumert TF, Lavillette D. Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model. J Biol Chem. 2015;290:23173-23187. [PMID: 26224633 DOI: 10.1074/jbc.m115.662999] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
49 Fang YP, Wu PC, Huang YB, Tzeng CC, Chen YL, Hung YH, Tsai MJ, Tsai YH. Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. Int J Nanomedicine 2012;7:4995-5005. [PMID: 23055719 DOI: 10.2147/IJN.S34301] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
50 Triyatni M, Berger EA, Saunier B. Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway. World J Hepatol 2016; 8(19): 796-814 [PMID: 27429716 DOI: 10.4254/wjh.v8.i19.796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
51 Budkowska A. Heterogeneity of Hepatitis C Virus Particles and Their Evolution During Infection. Cell Mol Gastroenterol Hepatol 2017;4:443-4. [PMID: 29062879 DOI: 10.1016/j.jcmgh.2017.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Li Y, Kakinami C, Li Q, Yang B, Li H. Human apolipoprotein A-I is associated with dengue virus and enhances virus infection through SR-BI. PLoS One. 2013;8:e70390. [PMID: 23894648 DOI: 10.1371/journal.pone.0070390] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
53 Vieyres G, Dubuisson J, Pietschmann T. Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion. Viruses. 2014;6:1149-1187. [PMID: 24618856 DOI: 10.3390/v6031149] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
54 Nevo-Yassaf I, Yaffe Y, Asher M, Ravid O, Eizenberg S, Henis YI, Nahmias Y, Hirschberg K, Sklan EH. Role for TBC1D20 and Rab1 in hepatitis C virus replication via interaction with lipid droplet-bound nonstructural protein 5A. J Virol 2012;86:6491-502. [PMID: 22491470 DOI: 10.1128/JVI.00496-12] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
55 Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RDG. Lipids and HCV. Semin Immunopathol 2013;35:87-100. [DOI: 10.1007/s00281-012-0356-2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
56 Yu T, Yang Q, Tian F, Chang H, Hu Z, Yu B, Han L, Xing Y, Jiu Y, He Y, Zhong J. Glycometabolism regulates hepatitis C virus release. PLoS Pathog 2021;17:e1009746. [PMID: 34297778 DOI: 10.1371/journal.ppat.1009746] [Reference Citation Analysis]
57 Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol 2020; 26(22): 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Heaton NS, Randall G. Multifaceted roles for lipids in viral infection. Trends Microbiol 2011;19:368-75. [PMID: 21530270 DOI: 10.1016/j.tim.2011.03.007] [Cited by in Crossref: 188] [Cited by in F6Publishing: 164] [Article Influence: 18.8] [Reference Citation Analysis]
59 Welte MA. Expanding roles for lipid droplets. Curr Biol 2015;25:R470-81. [PMID: 26035793 DOI: 10.1016/j.cub.2015.04.004] [Cited by in Crossref: 284] [Cited by in F6Publishing: 258] [Article Influence: 56.8] [Reference Citation Analysis]
60 Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA. 2003;100:7271-7276. [PMID: 12761383 DOI: 10.1073/pnas.0832180100] [Cited by in Crossref: 612] [Cited by in F6Publishing: 593] [Article Influence: 34.0] [Reference Citation Analysis]
61 Chatel-Chaix L, Bartenschlager R. Dengue virus- and hepatitis C virus-induced replication and assembly compartments: the enemy inside--caught in the web. J Virol 2014;88:5907-11. [PMID: 24623440 DOI: 10.1128/JVI.03404-13] [Cited by in Crossref: 78] [Cited by in F6Publishing: 58] [Article Influence: 11.1] [Reference Citation Analysis]
62 Pène V, Lemasson M, Harper F, Pierron G, Rosenberg AR. Role of cleavage at the core-E1 junction of hepatitis C virus polyprotein in viral morphogenesis. PLoS One 2017;12:e0175810. [PMID: 28437468 DOI: 10.1371/journal.pone.0175810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Boyer A, Dumans A, Beaumont E, Etienne L, Roingeard P, Meunier JC. The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles. J Biol Chem. 2014;289:18904-18913. [PMID: 24838241 DOI: 10.1074/jbc.m113.538256] [Cited by in Crossref: 65] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
64 Negro F. Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res. 2009;2009:483485. [PMID: 19132131 DOI: 10.1155/2009/483485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
65 Kawaguchi Y, Mizuta T. Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol 2014; 20(11): 2888-2901 [PMID: 24659880 DOI: 10.3748/wjg.v20.i11.2888] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 30] [Article Influence: 6.1] [Reference Citation Analysis]
66 Chan RB, Tanner L, Wenk MR. Implications for lipids during replication of enveloped viruses. Chem Phys Lipids 2010;163:449-59. [PMID: 20230810 DOI: 10.1016/j.chemphyslip.2010.03.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
67 Shrivastava S, Devhare P, Sujijantarat N, Steele R, Kwon YC, Ray R, Ray RB. Knockdown of Autophagy Inhibits Infectious Hepatitis C Virus Release by the Exosomal Pathway. J Virol. 2016;90:1387-1396. [PMID: 26581990 DOI: 10.1128/jvi.02383-15] [Cited by in Crossref: 88] [Cited by in F6Publishing: 60] [Article Influence: 14.7] [Reference Citation Analysis]
68 Harada R, Kimura M, Sato Y, Taniguchi T, Tomonari T, Tanaka T, Tanaka H, Muguruma N, Shinomiya H, Honda H, Imoto I, Sogabe M, Okahisa T, Takayama T. APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism. BMC Gastroenterol 2018;18:24. [PMID: 29382324 DOI: 10.1186/s12876-018-0747-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
69 Matto M, Sklan EH, David N, Melamed-Book N, Casanova JE, Glenn JS, Aroeti B. Role for ADP ribosylation factor 1 in the regulation of hepatitis C virus replication. J Virol. 2011;85:946-956. [PMID: 21068255 DOI: 10.1128/jvi.00753-10] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
70 Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA. 2007;104:5848-5853. [PMID: 17376867 DOI: 10.1073/pnas.0700760104] [Cited by in Crossref: 400] [Cited by in F6Publishing: 393] [Article Influence: 28.6] [Reference Citation Analysis]
71 Jiang J, Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol. 2009;83:12680-12691. [PMID: 19793818 DOI: 10.1128/jvi.01476-09] [Cited by in Crossref: 191] [Cited by in F6Publishing: 119] [Article Influence: 15.9] [Reference Citation Analysis]
72 Baldick CJ, Wichroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, Pokornowski KA, Rose RE, Eggers BJ, Hsu M, Zhai W, Zhai G, Gerritz SW, Poss MA, Meanwell NA, Cockett MI, Tenney DJ. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog 2010;6:e1001086. [PMID: 20838466 DOI: 10.1371/journal.ppat.1001086] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 6.1] [Reference Citation Analysis]
73 Unger LW, Forstner B, Schneglberger S, Muckenhuber M, Eigenbauer E, Scheiner B, Mandorfer M, Trauner M, Reiberger T. Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. Wien Klin Wochenschr. 2019;131:395-403. [PMID: 31493100 DOI: 10.1007/s00508-019-01544-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Oliveira KG, Malta FM, Nastri AC, Widman A, Faria PL, Santana RA, Alves VA, Carrilho FJ, Pinho JR. Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3. Med Microbiol Immunol 2016;205:111-7. [PMID: 26272127 DOI: 10.1007/s00430-015-0431-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
75 Speliotes EK, Balakrishnan M, Friedman LS, Corey KE. Treatment of Dyslipidemia in Common Liver Diseases. Clin Gastroenterol Hepatol 2018;16:1189-96. [PMID: 29684459 DOI: 10.1016/j.cgh.2018.04.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
76 Diaz O, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, Trépo C, Lotteau V, André P. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol. 2006;87:2983-2991. [PMID: 16963757 DOI: 10.1099/vir.0.82033-0] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 5.3] [Reference Citation Analysis]
77 Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol 2013; 19(41): 6947-6956 [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
78 Siqueira ER, Oliveira CP, Muniz MT, Silva F, Pereira LM, Carrilho FJ. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high plasma homocysteine in chronic hepatitis C (CHC) infected patients from the Northeast of Brazil. Nutr J 2011;10:86. [PMID: 21854603 DOI: 10.1186/1475-2891-10-86] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
79 Pietschmann T, Zayas M, Meuleman P, Long G, Appel N, Koutsoudakis G, Kallis S, Leroux-Roels G, Lohmann V, Bartenschlager R. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog. 2009;5:e1000475. [PMID: 19521536 DOI: 10.1371/journal.ppat.1000475] [Cited by in Crossref: 102] [Cited by in F6Publishing: 97] [Article Influence: 8.5] [Reference Citation Analysis]
80 Freedman H, Logan MR, Hockman D, Koehler Leman J, Law JLM, Houghton M. Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus. J Virol 2017;91:e02309-16. [PMID: 28148799 DOI: 10.1128/JVI.02309-16] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
81 Fuerst TR, Pierce BG, Keck ZY, Foung SKH. Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus. Front Microbiol 2017;8:2692. [PMID: 29379486 DOI: 10.3389/fmicb.2017.02692] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
82 Chida T, Kawata K, Ohta K, Matsunaga E, Ito J, Shimoyama S, Yamazaki S, Noritake H, Suzuki T, Suda T, Kobayashi Y. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b. Gut Liver 2018;12:201-7. [PMID: 29212314 DOI: 10.5009/gnl17179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
83 Li HC, Yang CH, Lo SY. Cellular factors involved in the hepatitis C virus life cycle. World J Gastroenterol 2021; 27(28): 4555-4581 [PMID: 34366623 DOI: 10.3748/wjg.v27.i28.4555] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Catanese MT, Loureiro J, Jones CT, Dorner M, von Hahn T, Rice CM. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol 2013;87:8282-93. [PMID: 23698298 DOI: 10.1128/JVI.01102-13] [Cited by in Crossref: 62] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
85 Miao Q, Ndao M. Trypanosoma cruzi infection and host lipid metabolism. Mediators Inflamm 2014;2014:902038. [PMID: 25276058 DOI: 10.1155/2014/902038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
86 Popescu CI, Rouillé Y, Dubuisson J. Hepatitis C virus assembly imaging. Viruses 2011;3:2238-54. [PMID: 22163343 DOI: 10.3390/v3112238] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
87 Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11:482-496. [PMID: 23748342 DOI: 10.1038/nrmicro3046] [Cited by in Crossref: 262] [Cited by in F6Publishing: 239] [Article Influence: 32.8] [Reference Citation Analysis]
88 Zhu YZ, Qian XJ, Zhao P, Qi ZT. How hepatitis C virus invades hepatocytes: The mystery of viral entry. World J Gastroenterol 2014; 20(13): 3457-3467 [PMID: 24707128 DOI: 10.3748/wjg.v20.i13.3457] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
89 Yamamoto S, Fukuhara T, Ono C, Uemura K, Kawachi Y, Shiokawa M, Mori H, Wada M, Shima R, Okamoto T, Hiraga N, Suzuki R, Chayama K, Wakita T, Matsuura Y. Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus. PLoS Pathog. 2016;12:e1005610. [PMID: 27152966 DOI: 10.1371/journal.ppat.1005610] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
90 Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis 2016;16:735-45. [PMID: 27301929 DOI: 10.1016/S1473-3099(16)00120-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 8.8] [Reference Citation Analysis]
91 Van Thiel DH, George M, Attar BM, Ramadori G, Ion-Nedelcu N. Plasma triglyceride levels may modulate hepatitis C viral replication. Dig Dis Sci 2014;59:881-5. [PMID: 24563239 DOI: 10.1007/s10620-014-3079-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Đorđević V, Stanković Đorđević D, Kocić B, Dinić M, Sokolović D, Pešić Stanković J. The Impact of Hepatitis C Virus Genotypes on Oxidative Stress Markers and Catalase Activity. Oxid Med Cell Longev 2021;2021:6676057. [PMID: 33708335 DOI: 10.1155/2021/6676057] [Reference Citation Analysis]
93 Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010;51:1904-1911. [PMID: 20235331 DOI: 10.1002/hep.23592] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 8.1] [Reference Citation Analysis]
94 Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol. 2007;81:8063-8071. [PMID: 17507483 DOI: 10.1128/jvi.00193-07] [Cited by in Crossref: 115] [Cited by in F6Publishing: 66] [Article Influence: 8.2] [Reference Citation Analysis]
95 Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, Zeisel MB, Herrmann E, Iken M, Ott M, Baumert TF, Pietschmann T. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog 2010;6:e1000978. [PMID: 20617177 DOI: 10.1371/journal.ppat.1000978] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 7.7] [Reference Citation Analysis]
96 Nielsen SU, Bassendine MF, Burt AD, Bevitt DJ, Toms GL. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 2004;85:1497-507. [PMID: 15166434 DOI: 10.1099/vir.0.79967-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
97 Takacs CN, Andreo U, Belote RL, Pulupa J, Scull MA, Gleason CE, Rice CM, Simon SM. Green fluorescent protein-tagged apolipoprotein E: A useful marker for the study of hepatic lipoprotein egress. Traffic 2017;18:192-204. [PMID: 28035714 DOI: 10.1111/tra.12467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
98 Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, Schwarz A, Moreau M, Owen JS, Leroux-Roels G, Balfe P, McKeating JA. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol 2007;81:3162-9. [PMID: 17215280 DOI: 10.1128/JVI.02356-06] [Cited by in Crossref: 115] [Cited by in F6Publishing: 69] [Article Influence: 8.2] [Reference Citation Analysis]
99 Rojas Á, Del Campo JA, Clement S, Lemasson M, García-Valdecasas M, Gil-Gómez A, Ranchal I, Bartosch B, Bautista JD, Rosenberg AR, Negro F, Romero-Gómez M. Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. Sci Rep 2016;6:31777. [PMID: 27546480 DOI: 10.1038/srep31777] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
100 Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, Xia J, Patel AH, Bukh J, Foung SK. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol 2013;87:37-51. [PMID: 23097455 DOI: 10.1128/JVI.01941-12] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 10.4] [Reference Citation Analysis]
101 Zapatero-Belinchón FJ, Ötjengerdes R, Sheldon J, Schulte B, Carriquí-Madroñal B, Brogden G, Arroyo-Fernández LM, Vondran FWR, Maasoumy B, von Hahn T, Gerold G. Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. Cells 2021;10:1626. [PMID: 34209751 DOI: 10.3390/cells10071626] [Reference Citation Analysis]
102 Siqueira ER, Oliveira CP, Correa-Giannella ML, Stefano JT, Cavaleiro AM, Fortes MA, Muniz MT, Silva FS, Pereira LM, Carrilho FJ. MTP -493G/T gene polymorphism is associated with steatosis in hepatitis C-infected patients. Braz J Med Biol Res. 2012;45:72-77. [PMID: 22147193 DOI: 10.1590/s0100-879x2011007500160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
103 Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol. 2011;85:596-605. [PMID: 20962076 DOI: 10.1128/jvi.01592-10] [Cited by in Crossref: 178] [Cited by in F6Publishing: 121] [Article Influence: 16.2] [Reference Citation Analysis]
104 Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol 2021; 27(13): 1267-1282 [PMID: 33833481 DOI: 10.3748/wjg.v27.i13.1267] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
105 Tabll A, Abbas AT, El-Kafrawy S, Wahid A. Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World J Hepatol 2015; 7(22): 2369-2383 [PMID: 26464752 DOI: 10.4254/wjh.v7.i22.2369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
106 Bartosch B, Dubuisson J. Recent advances in hepatitis C virus cell entry. Viruses 2010;2:692-709. [PMID: 21994653 DOI: 10.3390/v2030692] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
107 Agaugué S, Perrin-Cocon L, André P, Lotteau V. Hepatitis C lipo-Viro-particle from chronically infected patients interferes with TLR4 signaling in dendritic cell. PLoS One 2007;2:e330. [PMID: 17389921 DOI: 10.1371/journal.pone.0000330] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
108 Patel K, Jhaveri R, George J, Qiang G, Kenedi C, Brown K, Cates C, Zekry A, Tillmann HL, Elliott L. Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. J Viral Hepat. 2011;18:331-337. [PMID: 20367801 DOI: 10.1111/j.1365-2893.2010.01310.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
109 Sidorkiewicz M, Grek-Kowalinska M, Piekarska A. Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment. Pathogens 2020;9:E514. [PMID: 32630479 DOI: 10.3390/pathogens9060514] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Herker E, Ott M. Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol Metab 2011;22:241-8. [PMID: 21497514 DOI: 10.1016/j.tem.2011.03.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 8.0] [Reference Citation Analysis]
111 Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramière C, Bartenschlager R, Penin F, Lotteau V, André P. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One. 2009;4:e4233. [PMID: 19156195 DOI: 10.1371/journal.pone.0004233] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 8.3] [Reference Citation Analysis]
112 Jardim ACG, Shimizu JF, Rahal P, Harris M. Plant-derived antivirals against hepatitis c virus infection. Virol J 2018;15:34. [PMID: 29439720 DOI: 10.1186/s12985-018-0945-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
113 Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol. 2006;80:2418-2428. [PMID: 16474148 DOI: 10.1128/jvi.80.5.2418-2428.2006] [Cited by in Crossref: 260] [Cited by in F6Publishing: 155] [Article Influence: 17.3] [Reference Citation Analysis]
114 Boyer A, Dreneau J, Dumans A, Burlaud-Gaillard J, Bull-Maurer A, Roingeard P, Meunier JC. Endoplasmic Reticulum Detergent-Resistant Membranes Accommodate Hepatitis C Virus Proteins for Viral Assembly. Cells. 2019;8. [PMID: 31121874 DOI: 10.3390/cells8050487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
115 Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
116 Hemeda AA, Ahmad Mohamed A, Aziz RK, Abdel-Hakeem MS, Ali-Tammam M. Impact of IL10, MTP, SOD2, and APOE Gene Polymorphisms on the Severity of Liver Fibrosis Induced by HCV Genotype 4. Viruses 2021;13:714. [PMID: 33924242 DOI: 10.3390/v13040714] [Reference Citation Analysis]
117 Russelli G, Pizzillo P, Iannolo G, Barbera F, Tuzzolino F, Liotta R, Traina M, Vizzini G, Gridelli B, Badami E, Conaldi PG. HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. PLoS One 2017;12:e0181683. [PMID: 28750044 DOI: 10.1371/journal.pone.0181683] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
118 Hueging K, Weller R, Doepke M, Vieyres G, Todt D, Wölk B, Vondran FW, Geffers R, Lauber C, Kaderali L. Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. PLoS One. 2015;10:e0134529. [PMID: 26226615 DOI: 10.1371/journal.pone.0134529] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
119 Tarr AW, Khera T, Hueging K, Sheldon J, Steinmann E, Pietschmann T, Brown RJ. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses 2015;7:3995-4046. [PMID: 26193307 DOI: 10.3390/v7072809] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
120 Rembeck K, Maglio C, Lagging M, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Norkrans G. PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet. 2012;13:82. [PMID: 22978414 DOI: 10.1186/1471-2350-13-82] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
121 Schaefer EAK, Meixiong J, Mark C, Deik A, Motola DL, Fusco D, Yang A, Brisac C, Salloum S, Lin W, Clish CB, Peng LF, Chung RT. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. World J Gastroenterol 2016; 22(45): 9954-9965 [PMID: 28018102 DOI: 10.3748/wjg.v22.i45.9954] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
122 Zeisel MB, Barth H, Schuster C, Baumert TF. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed) 2009;14:3274-85. [PMID: 19273272 DOI: 10.2741/3450] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
123 Carpentier A, Tesfaye A, Chu V, Nimgaonkar I, Zhang F, Lee SB, Thorgeirsson SS, Feinstone SM, Liang TJ. Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J Clin Invest. 2014;124:4953-4964. [PMID: 25295540 DOI: 10.1172/jci75456] [Cited by in Crossref: 104] [Cited by in F6Publishing: 65] [Article Influence: 14.9] [Reference Citation Analysis]
124 Ye J. Hepatitis C virus: a new class of virus associated with particles derived from very low-density lipoproteins. Arterioscler Thromb Vasc Biol. 2012;32:1099-1103. [PMID: 22517369 DOI: 10.1161/atvbaha.111.241448] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
125 Liefhebber JM, Hague CV, Zhang Q, Wakelam MJ, McLauchlan J. Modulation of triglyceride and cholesterol ester synthesis impairs assembly of infectious hepatitis C virus. J Biol Chem. 2014;289:21276-21288. [PMID: 24917668 DOI: 10.1074/jbc.m114.582999] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
126 Fukuhara T, Wada M, Nakamura S, Ono C, Shiokawa M, Yamamoto S, Motomura T, Okamoto T, Okuzaki D, Yamamoto M. Amphipathic α-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles. PLoS Pathog. 2014;10:e1004534. [PMID: 25502789 DOI: 10.1371/journal.ppat.1004534] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
127 Dorna Mde S, Costa NA, Oliveira EP, Sassaki LY, Romeiro FG, Paiva SA, Minicucci MF, Silva GF. Association between phase angle, anthropometric measurements, and lipid profile in HCV-infected patients. Clinics (Sao Paulo) 2013;68:1555-8. [PMID: 24473515 DOI: 10.6061/clinics/2013(12)13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
128 Suzuki T. Morphogenesis of infectious hepatitis C virus particles. Front Microbiol. 2012;3:38. [PMID: 22347224 DOI: 10.3389/fmicb.2012.00038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
129 Guo J, Yan R, Xu GD, Zheng CY. HCV NS5A and NS5B enhance expression of human ceramide glucosyltransferase gene. Virol Sin 2012;27:38-47. [PMID: 22270805 DOI: 10.1007/s12250-012-3226-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
130 Goldwasser J, Cohen PY, Lin W, Kitsberg D, Balaguer P, Polyak SJ, Chung RT, Yarmush ML, Nahmias Y. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol. 2011;55:963-971. [PMID: 21354229 DOI: 10.1016/j.jhep.2011.02.011] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 8.1] [Reference Citation Analysis]
131 Pöhlmann S, Zhang J, Baribaud F, Chen Z, Leslie GJ, Lin G, Granelli-Piperno A, Doms RW, Rice CM, McKeating JA. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol. 2003;77:4070-4080. [PMID: 12634366 DOI: 10.1128/jvi.77.7.4070-4080.2003] [Cited by in Crossref: 287] [Cited by in F6Publishing: 147] [Article Influence: 15.9] [Reference Citation Analysis]
132 Martin C, Nielsen SU, Ibrahim S, Bassendine MF, Toms GL. Binding of liver derived, low density hepatitis C virus to human hepatoma cells. J Med Virol. 2008;80:816-823. [PMID: 18360895 DOI: 10.1002/jmv.21150] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
133 Pietschmann T, Zayas M, Meuleman P, Long G, Appel N, Koutsoudakis G, Kallis S, Leroux-Roels G, Lohmann V, Bartenschlager R. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog. 2009;5:e1000475. [PMID: 19521536 DOI: 10.1371/journal.ppat.1000475.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Perrin-Cocon L, Agaugué S, Diaz O, Vanbervliet B, Dollet S, Guironnet-Paquet A, André P, Lotteau V. Th1 disabled function in response to TLR4 stimulation of monocyte-derived DC from patients chronically-infected by hepatitis C virus. PLoS One. 2008;3:e2260. [PMID: 18509450 DOI: 10.1371/journal.pone.0002260] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
135 Brar I, Baxa D, Markowitz N. HCV enters the twenty-first century. Curr Infect Dis Rep 2013;15:52-60. [PMID: 23263749 DOI: 10.1007/s11908-012-0313-1] [Reference Citation Analysis]
136 Branche E, Conzelmann S, Parisot C, Bedert L, Lévy PL, Bartosch B, Clément S, Negro F. Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein. PLoS One 2016;11:e0146000. [PMID: 26731658 DOI: 10.1371/journal.pone.0146000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
137 Caldwell S, Hoehn KL, Hahn YS. The strange and critical intersection of hepatitis C and lipoprotein metabolism: "C-zing" the oil. Hepatology 2013;57:1684-7. [PMID: 23055122 DOI: 10.1002/hep.26091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003;197:633-642. [PMID: 12615904 DOI: 10.1084/jem.20021756] [Cited by in Crossref: 844] [Cited by in F6Publishing: 814] [Article Influence: 46.9] [Reference Citation Analysis]
139 Guan M, Wang W, Liu X, Tong Y, Liu Y, Ren H, Zhu S, Dubuisson J, Baumert TF, Zhu Y. Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem. 2012;287:35631-35645. [PMID: 22927442 DOI: 10.1074/jbc.m112.382341] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
140 Haid S, Windisch MP, Bartenschlager R, Pietschmann T. Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol 2010;84:964-75. [PMID: 19889758 DOI: 10.1128/JVI.01504-09] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
141 Sidorkiewicz M. Hepatitis C Virus Uses Host Lipids to Its Own Advantage. Metabolites 2021;11:273. [PMID: 33925362 DOI: 10.3390/metabo11050273] [Reference Citation Analysis]
142 Douam F, Ploss A. Proteomic approaches to analyzing hepatitis C virus biology. Proteomics 2015;15:2051-65. [PMID: 25809442 DOI: 10.1002/pmic.201500009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Schöbel A, Rösch K, Herker E. Functional innate immunity restricts Hepatitis C Virus infection in induced pluripotent stem cell-derived hepatocytes. Sci Rep 2018;8:3893. [PMID: 29497123 DOI: 10.1038/s41598-018-22243-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
144 Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab. 2010;21:33-40. [PMID: 19854061 DOI: 10.1016/j.tem.2009.07.005] [Cited by in Crossref: 227] [Cited by in F6Publishing: 222] [Article Influence: 18.9] [Reference Citation Analysis]
145 Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 2007;3:e108. [PMID: 17784784 DOI: 10.1371/journal.ppat.0030108] [Cited by in Crossref: 102] [Cited by in F6Publishing: 101] [Article Influence: 7.3] [Reference Citation Analysis]
146 Tews BA, Popescu CI, Dubuisson J. Last stop before exit - hepatitis C assembly and release as antiviral drug targets. Viruses 2010;2:1782-803. [PMID: 21994707 DOI: 10.3390/v2081782] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
147 Lai CK, Saxena V, Tseng CH, Jeng KS, Kohara M, Lai MM. Nonstructural protein 5A is incorporated into hepatitis C virus low-density particle through interaction with core protein and microtubules during intracellular transport. PLoS One 2014;9:e99022. [PMID: 24905011 DOI: 10.1371/journal.pone.0099022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
148 Tao J, Kang KD, Hall SD, Laube AH, Liu J, Renfrow MB, Novak J, Luo G. The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection. J Virol 2015;89:6782-91. [PMID: 25903344 DOI: 10.1128/JVI.00194-15] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
149 Gozdek A, Zhukov I, Polkowska A, Poznanski J, Stankiewicz-Drogon A, Pawlowicz JM, Zagórski-Ostoja W, Borowski P, Boguszewska-Chachulska AM. NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. Antimicrob Agents Chemother 2008;52:393-401. [PMID: 18039921 DOI: 10.1128/AAC.00961-07] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
150 Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A, Larrey D. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol. 2008;82:569-574. [PMID: 17942559 DOI: 10.1128/jvi.01443-07] [Cited by in Crossref: 110] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
151 Falcón V, Acosta-Rivero N, González S, Dueñas-Carrera S, Martinez-Donato G, Menéndez I, Garateix R, Silva JA, Acosta E, Kourı J. Ultrastructural and biochemical basis for hepatitis C virus morphogenesis. Virus Genes 2017;53:151-64. [PMID: 28233195 DOI: 10.1007/s11262-017-1426-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
152 Atoom AM, Taylor NG, Russell RS. The elusive function of the hepatitis C virus p7 protein. Virology 2014;462-463:377-87. [PMID: 25001174 DOI: 10.1016/j.virol.2014.04.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
153 Pietschmann T, Zayas M, Meuleman P, Long G, Appel N, Koutsoudakis G, Kallis S, Leroux-Roels G, Lohmann V, Bartenschlager R. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog. 2009;5:e1000475. [PMID: 19521536 DOI: 10.1371/journal.ppat] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
154 Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol. 2010;84:12048-12057. [PMID: 20826689 DOI: 10.1128/jvi.01063-10] [Cited by in Crossref: 104] [Cited by in F6Publishing: 72] [Article Influence: 9.5] [Reference Citation Analysis]
155 Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol. 2007;81:13783-13793. [PMID: 17913825 DOI: 10.1128/jvi.01091-07] [Cited by in Crossref: 319] [Cited by in F6Publishing: 198] [Article Influence: 22.8] [Reference Citation Analysis]
156 Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virus. J Gastroenterol 2007;42:411-23. [DOI: 10.1007/s00535-007-2030-3] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 6.1] [Reference Citation Analysis]
157 Eng FJ, El-Shamy A, Doyle EH, Klepper A, Muerhoff AS, Branch AD. Newly discovered hepatitis C virus minicores circulate in human blood. Hepatol Commun 2018;2:21-8. [PMID: 29404509 DOI: 10.1002/hep4.1125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Crouchet E, Lefèvre M, Verrier ER, Oudot MA, Baumert TF, Schuster C. Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux. Gut 2017;66:896-907. [PMID: 27609828 DOI: 10.1136/gutjnl-2015-311289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
159 Colpitts CC, Tsai PL, Zeisel MB. Hepatitis C Virus Entry: An Intriguingly Complex and Highly Regulated Process. Int J Mol Sci 2020;21:E2091. [PMID: 32197477 DOI: 10.3390/ijms21062091] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
160 Faustino AF, Martins IC, Carvalho FA, Castanho MA, Maurer-Stroh S, Santos NC. Understanding Dengue Virus Capsid Protein Interaction with Key Biological Targets. Sci Rep. 2015;5:10592. [PMID: 26161501 DOI: 10.1038/srep10592] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
161 Yost SA, Wang Y, Marcotrigiano J. Hepatitis C Virus Envelope Glycoproteins: A Balancing Act of Order and Disorder. Front Immunol 2018;9:1917. [PMID: 30197646 DOI: 10.3389/fimmu.2018.01917] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
162 Moriishi K, Matsuura Y. Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol. 2012;3:54. [PMID: 22347882 DOI: 10.3389/fmicb.2012.00054] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
163 Coller KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, Randall G. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog 2012;8:e1002466. [PMID: 22241992 DOI: 10.1371/journal.ppat.1002466] [Cited by in Crossref: 128] [Cited by in F6Publishing: 118] [Article Influence: 14.2] [Reference Citation Analysis]
164 Crouchet E, Baumert TF, Schuster C. Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact. Expert Rev Proteomics 2017;14:593-606. [PMID: 28625086 DOI: 10.1080/14789450.2017.1344102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
165 Delang L, Coelmont L, Neyts J. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses 2010;2:826-66. [PMID: 21994657 DOI: 10.3390/v2040826] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
166 Amako Y, Syed GH, Siddiqui A. Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein. J Biol Chem. 2011;286:11265-11274. [PMID: 21285358 DOI: 10.1074/jbc.m110.182097] [Cited by in Crossref: 67] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
167 Ogden SC, Tang H. The missing pieces of the HCV entry puzzle. Future Virol 2015;10:415-28. [PMID: 25960762 DOI: 10.2217/FVL.15.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
168 Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012;86:7256-67. [PMID: 22532692 DOI: 10.1128/JVI.07222-11] [Cited by in Crossref: 122] [Cited by in F6Publishing: 83] [Article Influence: 13.6] [Reference Citation Analysis]
169 Vere CC, Streba CT, Streba L, Rogoveanu I. Statins in the treatment of hepatitis C. Hepat Mon 2012;12:369-71. [PMID: 22879825 DOI: 10.5812/hepatmon.5998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
170 Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol. 2013;87:5270-5286. [PMID: 23449803 DOI: 10.1128/jvi.03022-12] [Cited by in Crossref: 129] [Cited by in F6Publishing: 80] [Article Influence: 16.1] [Reference Citation Analysis]
171 Valkov I, Ivanova R, Alexiev A, Antonov K, Mateva L. Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C. J Clin Diagn Res 2017;11:OC15-20. [PMID: 28969178 DOI: 10.7860/JCDR/2017/28609.10459] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
172 Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pécheur EI, Pietschmann T. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 2010;84:5751-63. [PMID: 20357091 DOI: 10.1128/JVI.02200-09] [Cited by in Crossref: 167] [Cited by in F6Publishing: 110] [Article Influence: 15.2] [Reference Citation Analysis]
173 Heaton NS, Randall G. Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe. 2010;8:422-432. [PMID: 21075353 DOI: 10.1016/j.chom.2010.10.006] [Cited by in Crossref: 399] [Cited by in F6Publishing: 381] [Article Influence: 39.9] [Reference Citation Analysis]
174 Di Lorenzo C, Angus AG, Patel AH. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011;3:2280-300. [PMID: 22163345 DOI: 10.3390/v3112280] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
175 Owen DM, Huang H, Ye J, Gale M Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology. 2009;394:99-108. [PMID: 19751943 DOI: 10.1016/j.virol.2009.08.037] [Cited by in Crossref: 162] [Cited by in F6Publishing: 158] [Article Influence: 13.5] [Reference Citation Analysis]
176 Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013;5:1292-1324. [PMID: 23698400 DOI: 10.3390/v5051292] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 11.6] [Reference Citation Analysis]
177 Ujino S, Nishitsuji H, Hishiki T, Sugiyama K, Takaku H, Shimotohno K. Hepatitis C virus utilizes VLDLR as a novel entry pathway. Proc Natl Acad Sci USA. 2016;113:188-193. [PMID: 26699506 DOI: 10.1073/pnas.1506524113] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
178 Boyer A, Park SB, de Boer YS, Li Q, Liang TJ. TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes. Gastroenterology 2018; 155: 1923-1935. e8. [PMID: 30144428 DOI: 10.1053/j.gastro.2018.08.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
179 Belouzard S, Danneels A, Fénéant L, Séron K, Rouillé Y, Dubuisson J. Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes. J Virol 2017;91:e00478-17. [PMID: 28659476 DOI: 10.1128/JVI.00478-17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
180 Toniutto P, Fabris C, Avellini C, Minisini R, Bitetto D, Rossi E, Smirne C, Pirisi M. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol 2005; 11(38): 5944-5950 [PMID: 16273604 DOI: 10.3748/wjg.v11.i38.5944] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
181 Lorizate M, Kräusslich HG. Role of lipids in virus replication. Cold Spring Harb Perspect Biol 2011;3:a004820. [PMID: 21628428 DOI: 10.1101/cshperspect.a004820] [Cited by in Crossref: 128] [Cited by in F6Publishing: 123] [Article Influence: 12.8] [Reference Citation Analysis]
182 Popescu CI, Riva L, Vlaicu O, Farhat R, Rouillé Y, Dubuisson J. Hepatitis C virus life cycle and lipid metabolism. Biology (Basel). 2014;3:892-921. [PMID: 25517881 DOI: 10.3390/biology3040892] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
183 Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol. 2009;83:6149-6160. [PMID: 19321602 DOI: 10.1128/jvi.00248-09] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
184 Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med. 2013;19:869-878. [PMID: 23836237 DOI: 10.1038/nm.3183] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 14.4] [Reference Citation Analysis]
185 Haid S, Pietschmann T, Pécheur EI. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem. 2009;284:17657-17667. [PMID: 19411248 DOI: 10.1074/jbc.m109.014647] [Cited by in Crossref: 68] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
186 Alzahrani N, Wu MJ, Shanmugam S, Yi M. Delayed by Design: Role of Suboptimal Signal Peptidase Processing of Viral Structural Protein Precursors in Flaviviridae Virus Assembly. Viruses 2020;12:E1090. [PMID: 32993149 DOI: 10.3390/v12101090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Jammart B, Michelet M, Pécheur EI, Parent R, Bartosch B, Zoulim F, Durantel D. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. J Virol. 2013;87:5065-5080. [PMID: 23427158 DOI: 10.1128/jvi.01405-12] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
188 Xu Y, Martinez P, Séron K, Luo G, Allain F, Dubuisson J, Belouzard S. Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. J Virol 2015;89:3846-58. [PMID: 25609801 DOI: 10.1128/JVI.03647-14] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
189 Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML, Morris CM, Burt AD, Donaldson PT. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut. 2006;55:715-718. [PMID: 16299033 DOI: 10.1136/gut.2005.079905] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 4.3] [Reference Citation Analysis]
190 Dao Thi VL, Granier C, Zeisel MB, Guérin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem. 2012;287:31242-31257. [PMID: 22767607 DOI: 10.1074/jbc.m112.365924] [Cited by in Crossref: 93] [Cited by in F6Publishing: 53] [Article Influence: 10.3] [Reference Citation Analysis]
191 Chan SW. Unfolded protein response in hepatitis C virus infection. Front Microbiol. 2014;5:233. [PMID: 24904547 DOI: 10.3389/fmicb.2014.00233] [Cited by in Crossref: 21] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
192 Vieyres G, Reichert I, Carpentier A, Vondran FWR, Pietschmann T. The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. PLoS Pathog. 2020;16:e1008554. [PMID: 32542055 DOI: 10.1371/journal.ppat.1008554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
193 Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S, Kugiyama Y, Nagata K, Nakamura M, Migita K, Nakao K. Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One. 2016;11:e0163644. [PMID: 27680885 DOI: 10.1371/journal.pone.0163644] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
194 Solbach P, Westhaus S, Deest M, Herrmann E, Berg T, Manns MP, Ciesek S, Sarrazin C, von Hahn T. Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cell Mol Gastroenterol Hepatol 2015;1:285-294.e1. [PMID: 28210681 DOI: 10.1016/j.jcmgh.2015.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
195 Syed GH, Khan M, Yang S, Siddiqui A. Hepatitis C Virus Lipoviroparticles Assemble in the Endoplasmic Reticulum (ER) and Bud off from the ER to the Golgi Compartment in COPII Vesicles. J Virol 2017;91:e00499-17. [PMID: 28515296 DOI: 10.1128/JVI.00499-17] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
196 Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence. Cells 2019;8:E376. [PMID: 31027278 DOI: 10.3390/cells8040376] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 18.0] [Reference Citation Analysis]
197 Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 2007;81:374-83. [PMID: 17050612 DOI: 10.1128/JVI.01134-06] [Cited by in Crossref: 187] [Cited by in F6Publishing: 126] [Article Influence: 12.5] [Reference Citation Analysis]
198 Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, Lagaye S, Pol S, Helle F, Plengpanich W. Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection. PLoS One. 2014;9:e92140. [PMID: 24646941 DOI: 10.1371/journal.pone.0092140] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
199 Weller R, Hueging K, Brown RJP, Todt D, Joecks S, Vondran FWR, Pietschmann T. Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. J Virol. 2017;91. [PMID: 28659481 DOI: 10.1128/jvi.00422-17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
200 Guevara J Jr, Prashad N, Ermolinsky B, Gaubatz JW, Kang D, Schwarzbach AE, Loose DS, Guevara NV. Apo B100 similarities to viral proteins suggest basis for LDL-DNA binding and transfection capacity. J Lipid Res 2010;51:1704-18. [PMID: 20173184 DOI: 10.1194/jlr.M003277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
201 Vausselin T, Calland N, Belouzard S, Descamps V, Douam F, Helle F, François C, Lavillette D, Duverlie G, Wahid A. The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology. 2013;58:86-97. [PMID: 23348596 DOI: 10.1002/hep.26273] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
202 Vieyres G, Pietschmann T. HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit. Cells 2019;8:E233. [PMID: 30871009 DOI: 10.3390/cells8030233] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
203 Pécheur EI. Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection. Scientifica (Cairo). 2012;2012:709853. [PMID: 24278733 DOI: 10.6064/2012/709853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
204 Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19:837-49. [PMID: 23836234 DOI: 10.1038/nm.3248] [Cited by in Crossref: 394] [Cited by in F6Publishing: 364] [Article Influence: 49.3] [Reference Citation Analysis]
205 Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, Chisari FV. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 2010;84:10999-1009. [PMID: 20686033 DOI: 10.1128/JVI.00526-10] [Cited by in Crossref: 157] [Cited by in F6Publishing: 98] [Article Influence: 14.3] [Reference Citation Analysis]
206 Stefas I, Tigrett S, Dubois G, Kaiser M, Lucarz E, Gobby D, Bray D, Ellerbrok H, Zarski JP, Veas F. Interactions between Hepatitis C Virus and the Human Apolipoprotein H Acute Phase Protein: A Tool for a Sensitive Detection of the Virus. PLoS One 2015;10:e0140900. [PMID: 26502286 DOI: 10.1371/journal.pone.0140900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
207 Pécheur EI, Diaz O, Molle J, Icard V, Bonnafous P, Lambert O, André P. Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis C virus glycoproteins. J Biol Chem 2010;285:25802-11. [PMID: 20551330 DOI: 10.1074/jbc.M110.131664] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
208 Gastaminza P, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol. 2006;80:11074-11081. [PMID: 16956946 DOI: 10.1128/jvi.01150-06] [Cited by in Crossref: 189] [Cited by in F6Publishing: 135] [Article Influence: 12.6] [Reference Citation Analysis]
209 Miao Z, Xie Z, Miao J, Ran J, Feng Y, Xia X. Regulated Entry of Hepatitis C Virus into Hepatocytes. Viruses 2017;9:E100. [PMID: 28486435 DOI: 10.3390/v9050100] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
210 Hughes MG Jr, Rosen HR. Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl 2009;15:1395-411. [PMID: 19877210 DOI: 10.1002/lt.21866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
211 Sung VM, Shimodaira S, Doughty AL, Picchio GR, Can H, Yen TS, Lindsay KL, Levine AM, Lai MM. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003;77:2134-46. [PMID: 12525648 DOI: 10.1128/jvi.77.3.2134-2146.2003] [Cited by in Crossref: 196] [Cited by in F6Publishing: 88] [Article Influence: 10.9] [Reference Citation Analysis]
212 Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009;50:1030-7. [PMID: 19787818 DOI: 10.1002/hep.23219] [Cited by in Crossref: 118] [Cited by in F6Publishing: 117] [Article Influence: 9.8] [Reference Citation Analysis]
213 Zeisel MB, Crouchet E, Baumert TF, Schuster C. Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses 2015;7:5659-85. [PMID: 26540069 DOI: 10.3390/v7112898] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
214 Menzel N, Fischl W, Hueging K, Bankwitz D, Frentzen A, Haid S, Gentzsch J, Kaderali L, Bartenschlager R, Pietschmann T. MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog. 2012;8:e1002829. [PMID: 22911431 DOI: 10.1371/journal.ppat.1002829] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 10.0] [Reference Citation Analysis]
215 Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU. Apolipoprotein c1 association with hepatitis C virus. J Virol 2008;82:9647-56. [PMID: 18667498 DOI: 10.1128/JVI.00914-08] [Cited by in Crossref: 107] [Cited by in F6Publishing: 58] [Article Influence: 8.2] [Reference Citation Analysis]
216 Mazumdar B, Banerjee A, Meyer K, Ray R. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology. 2011;54:1149-1156. [PMID: 21735466 DOI: 10.1002/hep.24523] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
217 Yu C, Boon D, Mcdonald SL, Myers TG, Tomioka K, Nguyen H, Engle RE, Govindarajan S, Emerson SU, Purcell RH. Pathogenesis of Hepatitis E Virus and Hepatitis C Virus in Chimpanzees: Similarities and Differences. J Virol 2010;84:11264-78. [DOI: 10.1128/jvi.01205-10] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
218 Ramière C, Rodriguez J, Enache LS, Lotteau V, André P, Diaz O. Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. J Virol. 2014;88:3246-3254. [PMID: 24390321 DOI: 10.1128/jvi.02862-13] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
219 Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008;82:12020-9. [PMID: 18829747 DOI: 10.1128/JVI.01569-08] [Cited by in Crossref: 129] [Cited by in F6Publishing: 78] [Article Influence: 9.9] [Reference Citation Analysis]
220 Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF. Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design. Front Immunol 2018;9:1436. [PMID: 29977246 DOI: 10.3389/fimmu.2018.01436] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
221 Grassi G, Di Caprio G, Fimia GM, Ippolito G, Tripodi M, Alonzi T. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol 2016; 22(6): 1953-1965 [PMID: 26877603 DOI: 10.3748/wjg.v22.i6.1953] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
222 Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines 2016;15:1535-44. [PMID: 27267297 DOI: 10.1080/14760584.2016.1194759] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
223 Rowell J, Thompson AJ, Guyton JR, Lao XQ, McHutchison JG, McCarthy JJ, Patel K. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int. 2012;6:475-481. [PMID: 21735316 DOI: 10.1007/s12072-011-9291-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
224 Gondar V, Molina-Jiménez F, Hishiki T, García-Buey L, Koutsoudakis G, Shimotohno K, Benedicto I, Majano PL. Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus. J Virol 2015;89:9962-73. [PMID: 26202245 DOI: 10.1128/JVI.00577-15] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
225 Strosberg AD, Kota S, Takahashi V, Snyder JK, Mousseau G. Core as a novel viral target for hepatitis C drugs. Viruses 2010;2:1734-51. [PMID: 21994704 DOI: 10.3390/v2081734] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
226 El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol 2012; 18(3): 212-224 [PMID: 22294824 DOI: 10.3748/wjg.v18.i3.212] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
227 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
228 Falson P, Bartosch B, Alsaleh K, Tews BA, Loquet A, Ciczora Y, Riva L, Montigny C, Montpellier C, Duverlie G, Pécheur EI, le Maire M, Cosset FL, Dubuisson J, Penin F. Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion. J Virol 2015;89:10333-46. [PMID: 26246575 DOI: 10.1128/JVI.00991-15] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
229 Lyu J, Imachi H, Fukunaga K, Yoshimoto T, Zhang H, Murao K. Roles of lipoprotein receptors in the entry of hepatitis C virus. World J Hepatol 2015; 7(24): 2535-2542 [PMID: 26527170 DOI: 10.4254/wjh.v7.i24.2535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
230 Nielsen SU, Bassendine MF, Martin C, Lowther D, Purcell PJ, King BJ, Neely D, Toms GL. Characterization of hepatitis C RNA-containing particles from human liver by density and size. J Gen Virol. 2008;89:2507-2517. [PMID: 18796720 DOI: 10.1099/vir.0.2008/000083-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
231 Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339. [PMID: 27595755 DOI: 10.1007/s11904-016-0333-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
232 Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 2012;56:484-91. [PMID: 22334503 DOI: 10.1002/hep.25665] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
233 Favre D, Muellhaupt B. Potential cellular receptors involved in hepatitis C virus entry into cells. Lipids Health Dis. 2005;4:9. [PMID: 15836798 DOI: 10.1186/1476-511x-4-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
234 Sabahi A. Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J. 2009;6:117. [PMID: 19643019 DOI: 10.1186/1743-422x-6-117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
235 Sabahi A, Marsh KA, Dahari H, Corcoran P, Lamora JM, Yu X, Garry RF, Uprichard SL. The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology 2010;407:110-9. [PMID: 20800257 DOI: 10.1016/j.virol.2010.07.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
236 Jung BK, Kim HR, Park GN, Luo G, Chang KS. Roles of human apolipoprotein E in the infectivity and replication of hepatitis C virus genotype 2a. J Microbiol 2016;54:451-8. [PMID: 27225463 DOI: 10.1007/s12275-016-6099-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
237 Ulsenheimer A, Paranhos-Baccalà G, Komurian-Pradel F, Raziorrouh B, Kurktschiev P, Diepolder HM, Zachoval R, Spannagl M, Jung MC, Gruener NH. Lack of variant specific CD8+ T-cell response against mutant and pre-existing variants leads to outgrowth of particular clones in acute hepatitis C. Virol J 2013;10:295. [PMID: 24073713 DOI: 10.1186/1743-422X-10-295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
238 Heller T, Saito S, Auerbach J, Williams T, Moreen TR, Jazwinski A, Cruz B, Jeurkar N, Sapp R, Luo G. An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A. 2005;102:2579-2583. [PMID: 15701697 DOI: 10.1073/pnas.0409666102] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 5.1] [Reference Citation Analysis]
239 Gentzsch J, Brohm C, Steinmann E, Friesland M, Menzel N, Vieyres G, Perin PM, Frentzen A, Kaderali L, Pietschmann T. hepatitis c Virus p7 is critical for capsid assembly and envelopment. PLoS Pathog 2013;9:e1003355. [PMID: 23658526 DOI: 10.1371/journal.ppat.1003355] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 10.9] [Reference Citation Analysis]
240 Gong Y, Cun W. The Role of ApoE in HCV Infection and Comorbidity. Int J Mol Sci. 2019;20:pii: E2037. [PMID: 31027190 DOI: 10.3390/ijms20082037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
241 Prentoe J, Bukh J. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. Front Immunol 2018;9:2146. [PMID: 30319614 DOI: 10.3389/fimmu.2018.02146] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
242 Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, Lauer GM, Chung RT. Acute hepatitis C infection lowers serum lipid levels. J Viral Hepat. 2011;18:e366-e371. [PMID: 21692949 DOI: 10.1111/j.1365-2893.2011.01434.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
243 Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ;  Virahep-C Study Group. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. 2010;52:854-863. [PMID: 20690192 DOI: 10.1002/hep.23796] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
244 Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008;82:2120-9. [PMID: 18077707 DOI: 10.1128/JVI.02053-07] [Cited by in Crossref: 339] [Cited by in F6Publishing: 215] [Article Influence: 24.2] [Reference Citation Analysis]
245 Villareal VA, Rodgers MA, Costello DA, Yang PL. Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses. Antiviral Res 2015;124:110-21. [PMID: 26526588 DOI: 10.1016/j.antiviral.2015.10.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
246 Gomaa HE, Mahmoud M, Saad NE, Saad-Hussein A, Ismail S, Thabet EH, Farouk H, Kandil D, Heiba A, Hafez W. Impact of Apo E gene polymorphism on HCV therapy related outcome in a cohort of HCV Egyptian patients. J Genet Eng Biotechnol. 2018;16:47-51. [PMID: 30647703 DOI: 10.1016/j.jgeb.2017.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
247 Owen DM, Huang H, Ye J, Gale M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology. 2009;394:99-108. [PMID: 19751943 DOI: 10.1016/j.virol.2009.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
248 Wang Y, Keck ZY, Foung SK. Neutralizing antibody response to hepatitis C virus. Viruses. 2011;3:2127-2145. [PMID: 22163337 DOI: 10.3390/v3112127] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]